AP 325

Drug Profile

AP 325

Alternative Names: AP-325

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Algiax Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neuropathic pain; Spinal cord injuries

Most Recent Events

  • 03 Aug 2017 Phase-II clinical trials in Neuropathic pain (PO) (Algiax pipeline, August 2017)
  • 03 Aug 2017 Phase-II clinical trials in Spinal cord injuries (Injection) (Algiax pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top